ENHANCEMENT OF THE SOLUBILITY AND THE DISSOLUTION RATE OF TAMOXIFEN CITRATE SOLID DISPERSION USING SOLUPLUS BY SOLVENT EVAPORATION TECHNIQUE

HAYDER HUSSEIN ABDULJABBAR, SHAIMAA NAZAR ABD ALHAMMID*
Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq. Email: shaimaapharmakon@gmail.com

Received: 04 August 2018, Revised and Accepted: 17 September 2018

ABSTRACT

Objective: The aim of the present study was the enhancement in the solubility of tamoxifen citrate using solid dispersion which is considered as a great solution to overcome the poor water solubility behavior of tamoxifen citrate (TMX) by solvent evaporation technique using Soluplus® as a novel carrier then formulate it as an orodispersible tablet.

Method: A total of 24 formulas were prepared as a solid dispersion by solvent evaporation method using Soluplus® as a polymeric solubilizer in the ratio of 1:1, 1.3, 1.5, 1.7, and 1:10 then formulated as orodispersible tablets by incorporating three types of superdisintegrants; croscarmellose, crospovidone, and sodium starch glycolate (SSG) with the solid dispersion. Characterization of the formulation was done using differential scanning colorimetry, Fourier transforms infrared spectroscopy, X-ray diffraction, and scanning electron microscope and the best formula was selected according to the disintegration and dissolution tests.

Results and Discussion: Formula 22 were selected as the best formula which contains mixed types of superdisintegrants; croscarmellose and SSG with the fastest complete disintegration of 6.5 s and complete dissolution with <2 min.

Conclusion: Accordingly, TMX was successfully enhanced its water solubility by converting its crystalline structure into the amorphous state through solid dispersion with Soluplus® and formulated as an orodispersible tablet to improve its oral absorption.

Keywords: Tamoxifen citrate, Solid dispersion, Soluplus®, Oral dispersible tablet, Superdisintegrants.

INTRODUCTION

One of the most challenging types of cancer is the breast cancer. Therefore, the incidence of it is remarkably rises making it the leading cause of mortality among all other types of cancer worldwide [1]. Tamoxifen citrate (TMX) has been used most commonly for the management of estrogen receptor breast cancer [2]. It is selective estrogen receptor modulator used in the treatment of early and advanced breast carcinoma in postmenopausal women [3].

On oral administration, only a limited amount of TMX is absorbed and reaches the blood circulation due to the low water solubility and an extensive first-pass metabolism [4,5]. Accordingly, there are numerous approaches attempted to overcome those obstacles one of them is by improving their water solubility through a nano sizing method or incorporation with coenzymes to avoid enzymatic degradation by the liver [5]. Solid dispersion is one of the approaches that used to improve the solubility of slightly soluble drugs like tamoxifen citrate since solid dispersion has many advantages like simplicity and low cost [6].

The solid dispersion can be defined as a dispersion of pharmacologically active substance through a matrix system. Usually, an inert carrier can be used which has the ability to disperse the drug in an aqueous medium either by reduce their particle size or convert it to an amorphous form leads to improve the solubility of the drug in water [7].

Many methods have been established to prepare a solid dispersion; solvent evaporation method is the most commonly used for small-scale preparation which include the dissolving both active pharmaceutical ingredient and the carrier in an organic solvent then allowed to evaporate to form a solid dispersion [7,8]. Furthermore, one of the most recent polymers that showed an enormous solubility enhancement is the Soluplus®, which is a polyethylene glycol polyvinyl caprolactam acetate grafted copolymer which is a novel thermoplastic internally plasticized amphiphilic polymer made for the preparation of solid dispersion with an excellent solubility enhancement and effective flowability characteristics [9].

To investigate the dissolution properties of TMX, Soluplus will be used to study its water solubility profile using solid dispersion and evaluate its characteristics by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), particle properties study, and measurement of phase solubility and dissolution behavior.

MATERIALS AND METHODS

Materials
Soluplus® obtained as a gift from BASF Germany. Crospovidone, croscarmellose (CC), sodium starch glycolate (SSG), mannitol, Aevic G102, and magnesium stearate obtained as a gift from Pioneer Pharmaceutical. TMX was purchased from Shijiazhuang Aopharm Import and Export Trading Co., Ltd.

Methods
Solid dispersion preparation
Solid dispersions were prepared using the solvent evaporation method with different TMX to Soluplus ratios such as 1:3, 1:5, 1:7, and 1:10.

Solvent evaporation method
An accurate amount of TMX was dissolved in a suitable amount of methanol, mixed thoroughly until it's completely dissolved, after that, Soluplus® was added to the organic solution and mixed using a magnetic stirrer for about 1 min then sonicated using an ultrasonicator for 10
more min to assure complete dissolution. The resultant solution kept overnight in a desiccator for drying [10].

**Characterization of TMX and solid dispersion powders**

**Thermodynamic solubility study**

Solubility study was conducted to investigate the apparent solubility of TMX and the solid dispersion powders prepared by a solvent evaporation method. An excess amount of each powder was added to a 5 ml distilled water in a screw-capped sealed container maintained under continuous shaking (200 rpm) and protected from light at room temperature (about 25°C) for 48 h to achieve an equilibrium. Samples were centrifuged, filtered using a 0.45 μ size Millipore and measured spectrophotometrically at 275 nm [4].

**DSC**

DSC was performed to examine the thermal behavior of TMX and the solid dispersion powder. The device used was Shimadzu, Japan DSC. A sample of about 5 mg of solid dispersion was packed inside a sealed aluminum pan and heated at a scanning rate of 10°C/min on a temperature range from 25°C to 300°C [11].

**FTIR spectroscopy**

FTIR was conducted to look into any alteration of the crystalline type of TMX after solid dispersion process. A sample of about 1 mg of the drug was grounded then mixed with potassium bromide and compressed through a manual press to form a thin disc and analyzed using FTIR spectroscopy in a range from 4000 to 400/cm [12].

**Powder X-ray diffraction (XRD)**

Diffraction model of TMX plain powder, Soluplus plain powder, and the selected solid dispersion formulation were attempted to determine the degree of crystallinity using (Shimadzu, Japan) X-ray diffractometer by utilizing Cu Kα radiation with a nickel filter, a voltage of 40 kV, and a current of 25 mA. The samples were analyzed in a range from 5°C to 50°C [12].

**Scanning electron microscopy (SEM) analysis**

The surface morphology of TMX powder and the selected solid dispersion formula were investigated using electron microscope (Shimadzu, Japan). The samples were mounted on a glass stub and coated with a thin layer of gold under vacuum for about 5 min in an argon atmosphere before an examination. Micro images with different magnifications were recorded to analyze surface characteristics of the solid dispersions [13].

**Powder evaluation**

**Flow characteristics of TMX powder and solid dispersions blends**

Flowability and compressibility are essential powder properties which are required for powder compression into tablets. According to USP pharmacopeia, an angle of repose test is used for measuring flowability of the powder. Furthermore, for compressibility, Hausner’s ratio and Carr’s index that determined using bulk density and tapped density measurement according to the following equation:

- **Carr’s index** = \( \frac{pp - pb}{pp} \times 100 \)

- **Bulk density represented** by \( pb \) (g/cm³)
- **Tapped density represented** by \( pp \) (g/cm³)
- **Hausner’s ratio** which is calculated according to the following equation:

\[ \text{Hausner's ratio} = \frac{\text{volume before tapping}}{\text{volume after tapping}}. \]

Flowability determination using the angle of repose test involves the use of a funnel technique in which the powder is allowed to flow throw a funnel of 1 cm in diameter and poured into a flat horizontal plate. The angle of repose then determined using the following equation:

\[ \tan \theta = \frac{h}{r} \]

In which, \( H \) is the tip height of the funnel from the surface plate and \( R \) is the radius of the circle that drawn around the powder pile [14].

**Orodispersible tablet preparation**

According to the solubility analysis, the optimized solid dispersion powders were selected and compressed into an orodispersible tablet and evaluated for further investigation. Different types of super disintegrants were used at different ratios as shown in Table 1: croscarmellose, crospovidone, and SSG. The compression of powder was made using a manual single punch press of 9 mm die and the tablets formed with a hardness of ±0.5 kg.

**Orodispersible tablet evaluation**

**In vitro disintegration time**

The disintegration time of the prepared orodispersible tablet was done through USP standard specified test. One tablet was held in a six holes basket and immersed in 900 ml phosphate buffer 6.8 in a fixed motion of raising and lowering at 30 cycles/min at 37.5°C. The time for complete disintegration of tablets was measured and recorded [15].

**In vitro dissolution time**

The dissolution of TMX was carried out using USP apparatus II, the paddle method, in 900 ml of 6.8 phosphate buffer at 37.5°C and the rotation speed of the paddle was 50 rpm using (Pharmatest, Germany). A 5 ml samples were with drown at time intervals of 2, 4, 6, 8, 10, 15, 20, 25, and 30 min and replaced with 5 ml of fresh dissolution medium for maintaining saturation solubility. The samples then filtered using 0.45 filter syringes and analyzed spectrophotometrically at 275 nm [16,17].

**Statistical analysis**

The results of the experiments are given as a mean of triplicate samples±standard deviation and were analyzed according to the t-test at the level of p<0.05 [18].

**RESULTS AND DISCUSSION**

**Thermodynamic solubility study**

The intrinsic solubility of TMX and its solid dispersion formulas were obtained and presented in Fig. 1. The results showed that there was a significant increase in the solubility of TMX by solid dispersion. A gradual water solubility increase as the concentration of Soluplus increased. For 1:3 ratio there is a small increase in water solubility when compared to 1:7 and 1:10 ratios and that could be due to that at a lower concentration of the carrier, a higher amount of TMX was not incorporated within the carrier. On the other hand, with a higher concentration of the carrier, a larger amount of TMX dispersed within the Soluplus and improved its wettability. At 1:1 ratio, it presented a paradoxical effect of decreasing in water solubility less than the pure drug. This can be explained due to the glass suspension of solid dispersion and formation of a viscous layer that delay the hydration of TMX particle [19].

**DSC**

The thermal behavior of TMX and solid dispersion was obtained and presented a sharp peak at 147 °C for TMX as shown in Fig. 2. On the contrary, the widening of this peak with solid dispersion and presented a sharp peak at 147 °C for TMX as shown in Fig. 2. On the other hand, Soluplus, showed well-defined characteristic peaks of the powder. Furthermore, for compressibility, Hausner’s ratio and Carr’s index that determined using bulk density and tapped density measurement according to the following equation:

\[ \text{Carr’s index} = \frac{pp - pb}{pp} \times 100 \]

Bulk density represented by \( pb \) (g/cm³)
- Tapped density represented by \( pp \) (g/cm³)
- Hausner’s ratio which is calculated according to the following equation:

\[ \text{Hausner's ratio} = \frac{\text{volume before tapping}}{\text{volume after tapping}}. \]

Flowability determination using the angle of repose test involves the use of a funnel technique in which the powder is allowed to flow throw a funnel of 1 cm in diameter and poured into a flat horizontal plate. The angle of repose then determined using the following equation:

\[ \tan \theta = \frac{h}{r} \]

In which, \( H \) is the tip height of the funnel from the surface plate and \( R \) is the radius of the circle that drawn around the powder pile [14].

**FTIR**

The results were obtained and showed a characteristic peak of TMX, Soluplus, and the selected solid dispersion formula. For TMX, it shows a sharp peak at 3080/cm for the aromatic (C-H) stretching, at 1124/cm for (C-O) stretching of ether, at 1704/cm for carbonyl stretching of carboxyl in dimmer, and at 2964/cm for the hydroxyl stretching of carboxylate. On the other hand, soluplus, showed well-defined characteristic peaks of the powder. Furthermore, for compressibility, Hausner’s ratio and Carr’s index that determined using bulk density and tapped density measurement according to the following equation:
which are; 3439 cm$^{-1}$ for (OH) stretching group, 2932 cm$^{-1}$ for aromatic (CH) stretching group, 1736 cm$^{-1}$ and 1638 cm$^{-1}$ for carbonyl stretching group and 1478 cm$^{-1}$ for (C-O-C) stretching group. The solid dispersion showed a shifting (OH) stretching group to 3460 cm$^{-1}$ due to a possible hydrogen bonding [20, 14].

Powder XRD

The results showed strong sharp peaks of TMX which are contributed to the higher degree of crystalline nature of its powder. The peaks of the solid dispersion were remarkably disappeared, due to the conversion of TMX from a crystalline state to an amorphous state. On the other hand in the physical mixture, peak intensities are clearly weakened when it compared to TMX alone but still present which indicates the presence of TMX crystals remaining in crystalline form (Fig. 4) [20].

SEM analysis

The results of SEM are illustrated in Fig. 5. The surface morphology of TMX showed a cluster of clear crystals indicates its crystallinity nature. On the contrary, the solid dispersion showed a smooth homogeneous surface characteristic as one piece and TMX loses its crystalline shape which indicated the conversion to an amorphous state by a solid dispersion [20].

Micromeritic powder evaluation

The result of the flow properties of powder is presented in Table 2. It can be seen that pure drug has poor powder flowability and compressibility features which significantly enhanced by solid dispersion through solvent evaporation method.
Orodispersible tablet evaluation

In vitro disintegration time

Time for complete disintegration is calculated and presented in Table 3. The results revealed that among all formulas which contain 10% of superdisintegrant, CC showed the shorter disintegration time which is contributed to its high swelling capacity due to hydrophilic, high absorbent nature, and an excellent wicking mechanism contributed to its fibrous nature [21].

On the other hand, among all formulas which contain 5% mixed of two type’s superdisintegrant CC with SSG combination showed the fastest disintegration time which is also the shortest among the rest of formulas which is contributed for dual disintegration synergistic action with rapid water intake of SSG and many different swelling and disintegration mechanisms of CC [22,23].

In vitro dissolution study

Dissolution study is a crucial study for tablets that exhibit a fast release pattern especially orodispersible tablets in which this process attempt in a matter of seconds. According to the results, TMX exhibited a poor dissolution behavior and remains floated for most of the time of the test which is contributed to the higher lipophilicity nature. On the contrary, solid dispersion formulas showed a significant rapid, sharp release as
Abduljabbar and Alhammid  
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 216-221

Table 2: Powder evaluation of pure drug and solid dispersion powder

| Powder      | Angle of repose | Carr’s index | Hausner’s ratio |
|-------------|-----------------|--------------|-----------------|
| Pure drug   | 43.5±0.41       | 38±0.81      | 2.6±0.08        |
| 1:3 SD      | 20±0.81         | 18.2±0.20    | 1.22±0.01       |
| 1:5 SD      | 20.6±0.38       | 16.8±0.16    | 1.23±0.026      |
| 1:7 SD      | 22.7±0.32       | 18.0±0.28    | 1.25±0.024      |
| 1:10 SD     | 24.2±0.35       | 12.67±0.53   | 1.18±0.012      |

*Mean±SD, n=3

Table 3: In vitro disintegration time of the formulas prepared by solvent evaporation

| Formula | Disintegration time (s) |
|---------|-------------------------|
| F1      | 8.4±0.31                |
| F2      | 17.6±0.47               |
| F3      | 9.06±0.09               |
| F4      | 7.6±0.28                |
| F5      | 8.2±0.2                 |
| F6      | 13.5±0.4                |
| F7      | 8.3±0.23                |
| F8      | 17.5±0.4                |
| F9      | 9.1±0.23                |
| F10     | 7.5±0.14                |
| F11     | 8.25±0.2                |
| F12     | 13.16±0.23              |
| F13     | 7.58±0.11               |
| F14     | 16.5±0.4                |
| F15     | 8.5±0.42                |
| F16     | 6.9±0.11                |
| F17     | 7.58±0.11               |
| F18     | 12.8±0.23               |
| F19     | 7.5±0.08                |
| F20     | 16.5±0.4                |
| F21     | 8.5±0.4                 |
| F22     | 6.7±0.2                 |
| F23     | 7.3±0.14                |
| F24     | 12.5±0.4                |

*Mean±SD, n=3

Selection of the best formula

According to the dissolution and the disintegration results, formula (F22) that contain a mixed proportion of CC and SSG of 5% of each one, was selected as the best formula with a faster disintegration time of 6.5 s and faster and sharper complete dissolution profile with <2 min.

Comparison between the selected formula and plain TMX

As presented in Fig. 10, formula F22 has faster and complete dissolution within 2 min which is highly significant than dissolution profile of plain TMX that showed slow with no complete dissolution. That may be explained by the preparation of solid dispersion using a solvent evaporation method can converts a crystalline nature of TMX to an amorphous state and enhances its water solubility, leads to an increase in its dissolution and disintegration rates.

CONCLUSION

TMX is an anticancer drug with a poor water solubility that was studied with Soluplus as a solubilizer which is, a novel polymeric carrier, using solid dispersion method through solvent evaporation technique then formulated as an orodispersible dosage form. The saturation solubility of TMX was significantly increased through all ratios of Soluplus and was the highest with 1:10 ratio that increases its water solubility by 23 folds.

Orodispersible tablets were formulated using three different types of super disintegrants; CC, crospovidone, and SSG. Formula (F22) was selected as the best formula with a dissolution time <2 min which makes it succeed as an orodispersible tablet. Consequently, Soluplus is a promising polymeric solubilizer for poorly water-soluble drugs that can increase its solubility and enhances its bioavailability.
AUTHOR’S CONTRIBUTION

Both authors have equally contributed.

CONFLICTS OF INTEREST

The authors declared that they have no conflicts of interest.

REFERENCES

1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 2005;6:391-401.

2. Ravikumara NR, Bharadwaj M, Madhusudhan B. Tamoxifen citrate-loaded poly(d,l) lactic acid nanoparticles: Evaluation for their anticancer activity in vitro and in vivo. J Biomater Appl 2016;31:1-18.

3. Beale, JM, Block JH. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry. 12th ed. Philadelphia, PA, USA: Lippincott, Williams and Wilkins; 2011. p. 834.

4. Elsaggar YS, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization. Int J Pharm 2009;380:133-41.

5. El-Leithy ES, Abdel-Rashid RS. Lipid nanocarriers for tamoxifen citrate/coenzyme Q10 dual delivery. J Drug Deliv Sci Technol 2017;41:239-50.

6. Meng F, Gala U, Chauhan H. Classification of solid dispersions: Correlation to (I) stability and solubility (II) preparation and characterization techniques. Drug Dev Ind Pharm 2015;41:1401-15.

7. Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: A review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci 2016;105:2527-44.

8. Yadav Sh K, Veena M, Srinivas M. Solid dispersion technique to enhance the solubility and dissolution rate of aripiprazole by fusion method. Int J Pharm Sci 2016;8:187-192.

9. Reginald-Opara JN, Attama A, Ofokansi K, Umeyor C, Kenechukwu F. Molecular interaction between glimepiride and soluplus-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies. Int J Pharm 2015;496:741-50.

10. Mohammadi G, Hemati V, Nikbakht MR, Mirzaei S, Fatahi A, Ghanbari K, et al. In vitro and in vivo evaluation of clarithromycin-urea solid dispersions prepared by solvent evaporation, electrospinning and freeze drying methods. Powder Technol 2014;257:168-74.

11. Fule R, Amin P. Development and evaluation of lafutidine solid dispersion via hot melt extrusion: Investigating drug-polymer miscibility with advanced characterisation. Asian J Pharm Sci 2014;9:92-106.

12. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid naringin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm 2015;41:772-9.

13. Huang Y, Dai WG. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B 2014;4:18-25.

14. Shamma RN, Basha M. Soluplus®: A novel polymeric solubilizer for optimization of carvedilol solid dispersions: Formulation design and effect of method of preparation. Powder Technol 2013;237:406-14.

15. Dave V, Yadav RB, Ahuja R, Sahu AK. Formulation and evaluation of orally dispersible tablets of chlorpheniramine maleate by fusion method. Marmara Pharm J 2017;21:67-77.

16. Shankarrao KA, Mahadeo GD, Balavantrao KP. Formulation and in vitro evaluation of orally disintegrating tablets of olanzapine-2-hydroxypropyl-beta-cyclodextrin inclusion complex. Iran J Pharm Res 2010;9:335-47.

17. Ge Z, Yang M, Wang Y, Shan L, Gao C. Preparation and evaluation of orally disintegrating tablets of taste masked phencyclodione HCl using ion-exchange resin. Drug Dev Ind Pharm 2015;41:934-41.

18. Kimura SI, Uchida S, Kanada K, Namiki N. Effect of granule properties on rough mouth feel and palatability of orally disintegrating tablets. Int J Pharm 2015;484:156-62.

19. Homayouni A, Sadeghi F, Nokhodchi A. Preparation and characterization of celecoxib dispersions in soluplus®: Comparison of spray drying and conventional methods. Iran J Pharm Res 2015;14:35-50.

20. Shuai S, Yue S, Huang Q, Wang W, Yang Y, Lan K, et al. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability. Eur J Drug Metab Pharmacocinet 2016;41:413-22.

21. Rao NR, Patel T, Gundy S. Development and evaluation of carbamazepine fast dissolving tablets prepared with a complex by direct compression technique. Asian J Pharm 2009;3:97-105.

22. Khairnar DA, Anantwar SP, Chaudhari CS, Shelke PA. Superdisintegrants: An emerging paradigm in orodispersible tablets. Int J Biopharm 2014;5:119-28.

23. Egl M, Abd Al hammid Sh N. Design zolmitryptan liquidisolid orodispersible tablets and their in vitro evaluation. Int J Pharm Sci 2017;9:297-303.